ProMIS Neurosciences (PMN) Short-term Investments (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Short-term Investments came in at $33753.0 in Q1 2026, up 2.12% YoY from $33051.0 in Q1 2025, and little changed on a QoQ basis from $33753.0 in Q4 2025.
ProMIS Neurosciences (PMN) Short-term Investments (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Short-term Investments data on file, last reported at $33753.0 in Q1 2026.
- Quarterly Short-term Investments rose 2.12% year-over-year to $33753.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33753.0 (up 2.12% YoY) and the FY2025 annual result came in at $33753.0, up 2.12% from the prior year.
- Short-term Investments steadied at $33753.0 in Q1 2026, from $33753.0 in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $33753.0 in Q4 2025 to a low of $30539.0 in Q3 2022.
- A 5-year average of $32385.0 and a median of $32358.0 in 2023 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2022 — Short-term Investments slipped 6.73% — and 2023, when it advanced 4.35%.
- Tracing PMN's Short-term Investments over 5 years: stood at $31009.0 in 2022, then gained by 4.35% to $32358.0 in 2023, then grew by 2.14% to $33051.0 in 2024, then grew by 2.12% to $33753.0 in 2025, then changed by 0.0% to $33753.0 in 2026.
- The last three Short-term Investments figures came in at $33753.0 (Q1 2026), $33753.0 (Q4 2025), and $33051.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33,753.00 |
| Mar 31, 2026 | 33,753.00 |
| Dec 31, 2025 | 33,753.00 |
| Sep 30, 2025 | 33,051.00 |
| Jun 30, 2025 | 33,051.00 |
| Mar 31, 2025 | 33,051.00 |
| Dec 31, 2024 | 33,051.00 |
| Sep 30, 2024 | 32,358.00 |
| Jun 30, 2024 | 32,358.00 |
| Mar 31, 2024 | 32,358.00 |
| Dec 31, 2023 | 32,358.00 |
| Sep 30, 2023 | 31,824.00 |
| Jun 30, 2023 | 31,825.00 |
| Mar 31, 2023 | 31,134.00 |
| Dec 31, 2022 | 31,009.00 |
| Sep 30, 2022 | 30,539.00 |
| Jun 30, 2022 | 32,687.00 |
| Dec 31, 2021 | 33,248.00 |